Related Experiment Video
Updated: Jul 15, 2025
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
9.9K
Metabolite Profile Characterization of Cyanobacterial Strains with Bioactivity on Lipid Metabolism Using In Vivo and
Tiago Ribeiro1,2, Kristín Jónsdóttir3, Rene Hernandez-Bautista4
1Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR), University of Porto, Avenida General Norton de Matos, s/n, 4450-208 Matosinhos, Portugal.
Marine Drugs
|September 27, 2023
Summary
Cyanobacteria extracts show promise for reducing lipids and improving metabolic health. Researchers identified 23 non-toxic fractions with bioactive compounds, including phosphatidic acid, for potential therapeutic use.
Area of Science:
- Biotechnology
- Pharmacology
- Metabolomics
Background:
- Cyanobacteria possess therapeutic potential for various human diseases.
- Metabolic disorders, such as obesity and fatty liver disease, represent a significant global health challenge.
- Natural products from microorganisms are a valuable source for drug discovery.
Purpose of the Study:
- To screen cyanobacterial extracts for lipid-reducing and glucose-uptake-enhancing activities.
- To identify bioactive compounds from cyanobacteria with potential therapeutic applications in metabolic disorders.
- To utilize advanced analytical techniques for metabolite profiling and compound identification.
Main Methods:
- Cultivation and fractionation of 39 cyanobacteria strains, yielding 117 extracts.
- In vitro assays using zebrafish larvae and human hepatocytes to assess lipid reduction and glucose uptake.
- Murine brown adipocyte model to evaluate uncoupling protein 1 (ucp1) mRNA induction.
- Untargeted Ultra-Performance Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry (UPLC-Q-TOF-MS) for metabolite profiling.
- Multivariate statistical analysis for prioritizing bioactive strains.
Main Results:
- Twelve cyanobacterial fractions demonstrated lipid reduction in zebrafish larvae, and five showed efficacy in a human hepatocyte steatosis model.
- Six fractions induced ucp1 mRNA expression in murine brown adipocytes, leading to 23 non-toxic bioactive fractions.
- Metabolite profiling identified phosphatidic acid and aromatic polyketides derivatives as potential markers for lipid reduction.
Conclusions:
- Cyanobacterial strains exhibit significant potential for developing novel therapeutics targeting lipid metabolism.
- The identified bioactive compounds, phosphatidic acid and polyketides, warrant further investigation for their role in metabolic health.
- Future research should focus on the detailed characterization and mechanism of action of these promising cyanobacterial compounds.
